Angiomyolipoma medical therapy: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is [[embolisation]] | There is no treatment for [[angiomyolipoma]]; the mainstay of therapy is surgical resection or [[embolisation]]. | ||
==Treatment== | ==Treatment== | ||
Revision as of 19:24, 22 September 2015
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma medical therapy |
|
Risk calculators and risk factors for Angiomyolipoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
There is no treatment for angiomyolipoma; the mainstay of therapy is surgical resection or embolisation.
Treatment
There is no treatment for angiomyolipoma; the mainstay of therapy is embolisation or resection. Angiomyolipomas found incidentally usually require no therapy Patients with kidney loss should be monitored for:
- Hypertension
- Nephrotoxic drugs such as:
- Certain pain relievers
- IV contrast agents
Rapamycin
Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.[1]
References
- ↑ Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.